Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

October 7, 2019

Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows

News

The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer (mCRPC), ... Read more

September 16, 2019

PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says

News

The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels of ... Read more

September 5, 2019

Collaborators Work to Develop New Sequencing Methods to Manage Cancers

News

The nonprofit organization Genome Canada, the pharmaceutical company Thermo Fisher Scientific and the Ontario Institute for Cancer Research (OICR) are collaborating to develop new targeted next generation sequencing (NGS) methods ... Read more

August 28, 2019

Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery

News

Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men ... Read more

August 26, 2019

Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic prostate ... Read more

August 22, 2019

PSMA-targeted Therapies Work Best in Tumors with Mutations in DNA Repair Genes, Study Suggests

News

Tumors with large numbers of prostate cancer cells with mutations in DNA repair genes are easier to target using prostate-specific membrane antigen (PSMA) therapies, and patients with these tumors are more ... Read more

August 1, 2019September 9, 2019

FDA Approves Nubeqa Tablets for Men with Non-metastatic Castration-resistant Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Nubeqa (darolutamide) tablets to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC). “We know that men with nmCRPC are still in ... Read more

July 29, 2019July 29, 2019

ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests

News

Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male ... Read more

July 11, 2019

Advantagene Reaches Enrollment Goal in Phase 2 Trial Testing Prostate Cancer Vaccine

News

Advantagene, also known as Candel Therapeutics, has reached its patient enrollment goal in an ongoing Phase 2 trial testing the effectiveness of ProstAtak, the company’s prostate cancer vaccine, among men ... Read more

June 12, 2019

Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows

News

Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and stabilizes their quality of life without increasing the incidence of ... Read more